This article is more than 5 years old. Information may no longer be current.

Alcon receives approval in Europe for fixed combination glaucoma drop

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

HUENENBERG, Switzerland — The European Medicines Agency has approved a fixed combination eye drop for treating elevated IOP associated with open-angle glaucoma or ocular hypertension in adults who are unresponsive to monotherapy, Alcon announced in a press release.

Clinical trials supporting the approval demonstrated that the active ingredients in Azarga ophthalmic suspension (brinzolamide 10 mg/mL and timolol 5 mg/mL) were more effective when delivered in combination than either ingredient alone. In addition, the drug demonstrated superior IOP-lowering efficacy and similar safety at follow-up vs. the individual components alone.

The drug will be available in Europe in early 2009, according to the release.